Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India.
Department of Diabetes & Endocrinology, G.D Hospital & Diabetes Institute, Kolkata, India.
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102282. doi: 10.1016/j.dsx.2021.102282. Epub 2021 Sep 16.
We aimed to know whether SGLT-2 inhibitors (SGLT-2I) exhibit similar cardiovascular (CV) benefit in patients having reduced ejection fraction heart failure (HFrEF) with varying degree of glycemia.
We meta-analyzed the trial-level hazard ratio and 95% confidence interval of randomized trials that reported the CV outcomes stratified in to three subgroups of normoglycemia, prediabetes and diabetes.
This meta-analysis found a significant and similar CV risk reduction in patients with HFrEF without any significant interaction between three subgroups (P = 0.98).
SGLT-2I exhibit similar CV risk reduction in HFrEF, regardless of baseline glycemic status. However, this finding is limited to pooled data from only 2 studies in people without T2DM.
我们旨在了解 SGLT-2 抑制剂（SGLT-2I）在射血分数降低的心力衰竭（HFrEF）伴有不同程度血糖的患者中是否具有相似的心血管（CV）获益。
我们对报告 CV 结局的随机试验进行了试验水平的风险比和 95%置信区间的荟萃分析，并将其分层为正常血糖、糖尿病前期和糖尿病三个亚组。
这项荟萃分析发现，在 HFrEF 患者中，SGLT-2I 显著且相似地降低了 CV 风险，且三个亚组之间没有显著的相互作用（P=0.98）。
SGLT-2I 在 HFrEF 中具有相似的 CV 风险降低作用，无论基线血糖状态如何。然而，这一发现仅限于来自没有 T2DM 的 2 项研究的汇总数据。
